A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs

Bacterial Factors That Predict Relapse after Tuberculosis Therapy

(2018) Roberto Colangeli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

(2016) A. Bekker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

(2016) Neesha Rockwood et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians

(2016) Jan-Willem C. Alffenaar et al.   CLINICAL INFECTIOUS DISEASES

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

(2016) Payam Nahid et al.   CLINICAL INFECTIOUS DISEASES

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

(2016) Marlanka A. Zuur et al.   Expert Opinion on Drug Metabolism & Toxicology

Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status

(2016) Geetha Ramachandran et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting

(2016) Natasha van’t Boveneind-Vrubleuskaya et al.   PLoS One

The challenges of pharmacokinetic variability of first-line anti-TB drugs

(2016) Bella Devaleenal Daniel et al.   Expert Review of Clinical Pharmacology

A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis

(2015) Martin J. Boeree et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis

(2015) Marieke G. G. Sturkenboom et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi

(2015) J. J. van Oosterhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children

(2015) Aparna Mukherjee et al.   BMC INFECTIOUS DISEASES

The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

(2015) Alper Daskapan et al.   EUROPEAN RESPIRATORY JOURNAL

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial

(2015) Antonia M. I. Saktiawati et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs

(2015) Hadija H. Semvua et al.   THERAPEUTIC DRUG MONITORING

Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection

(2015) Awewura Kwara et al.   Journal of the Pediatric Infectious Diseases Society

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

(2015) Paolo Denti et al.   PLoS One

Nutritional Supplementation Increases Rifampin Exposure among Tuberculosis Patients Coinfected with HIV

(2014) Kidola Jeremiah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of First-Line Antituberculosis Drugs in HIV-Infected Children with Tuberculosis Treated with Intermittent Regimens in India

(2014) Geetha Ramachandran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients

(2014) Ana Requena-Méndez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins

(2014) Mario Regazzi et al.   CLINICAL PHARMACOKINETICS

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

(2014) Abdullah Alsultan et al.   DRUGS

Understanding pharmacokinetics to improve tuberculosis treatment outcome

(2014) Jonathan Reynolds et al.   Expert Opinion on Drug Metabolism & Toxicology

Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS

(2014) D.H. Vu et al.   TALANTA

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines

(2012) Helen McIlleron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV

(2012) Ana Requena-Méndez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dried Blood Spot Analysis Combined With Limited Sampling Models Can Advance Therapeutic Drug Monitoring of Tuberculosis Drugs

(2012) J.-W. C. Alffenaar   JOURNAL OF INFECTIOUS DISEASES

TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

(2011) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients

(2011) Siv Jönsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

(2011) J. van Ingen et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

(2011) Shashikant Srivastava et al.   JOURNAL OF INFECTIOUS DISEASES

Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations

(2010) M. Weiner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV Infection–Associated Tuberculosis: The Epidemiology and the Response

(2010) Haileyesus Getahun et al.   CLINICAL INFECTIOUS DISEASES

Effect of treating co-infections on HIV-1 viral load: a systematic review

(2010) Kayvon Modjarrad et al.   LANCET INFECTIOUS DISEASES

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

(2009) Hendrik Simon Schaaf et al.   BMC Medicine

Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

(2009) Sekai Chideya et al.   CLINICAL INFECTIOUS DISEASES

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Therapeutic Drug Monitoring of Nevirapine in Resource‐Limited Settings

(2008) Rafaëlla F. A. L’homme et al.   CLINICAL INFECTIOUS DISEASES